Quantcast

Comparison of a twice-daily injection of insulin aspart 50 with insulin aspart 30 in patients with poorly controlled type 2 diabetes.

Research paper by Chunhong C Shi, Luyan L Sun, Ran R Bai, Hao H Wang, Dan D Liu, Jianling J Du

Indexed on: 15 Dec '18Published on: 15 Dec '18Published in: Current medical research and opinion



Abstract

To compare the efficacy and safety of a twice-daily injection of insulin aspart (BIAsp) 30 and BIAsp50 in patients with type 2 diabetes mellitus (T2DM) poorly controlled with oral hypoglycaemic agents (OHAs). In this 12-week prospective, randomized, parallel trial, a total of 80 T2DM patients, 59 ± 10 years old with a disease duration of 9.3 ± 6.6 years and HbA1c > 7% despite large doses of metformin and sulfonylurea administration, were randomized to receive BIAsp30 (n = 40) or BIAsp50 (n = 40). The primary endpoint was a change in HbA1c at week 12. The changes in HbA1c from baseline were [-(2.5 ± 1.0)%] in the BIAsp50 group and [-(2.5 ± 1.2)%] in the BIAsp30 group (P = 0.897). No difference was observed in the rate of HbA1c target achievement (< 7.0%) between BIAsp50 (42.5%) and BIAsp30 (32.5%) (P = 0.495). The change in fasting plasma glucose (FPG) in the BIAsp50 group was lower than that in the BIAsp30 group (P = 0.000), while the change in two-hour postprandial blood glucose (2hPBG) was higher and blood glucose excursion was lower in the BIAsp50 group than that in the BIAsp30 group (P = 0.000, P = 0.000). A significant improvement in HbA1c was observed with BIAsp50 in subgroups with baseline blood glucose excursion >7.8 mmol/L or 2hPBG >17.6 mmol/L compared with BIAsp30 . There were no differences in hypoglycaemia and body weight between groups. Compared with BIAsp30, BIAsp50 showed greater efficacy in patients with baseline BG excursion >7.8 mmol/L or 2hPBG >17.6 mmol/L as well as good safety for hypoglycaemia. ChiCTR-IIR-16008958.

More like this: